Year Founded
2019
Ownership
Private
Employees
~50
Stage
Phase 1
Modalities
Antibody-based immunotherapy

Immunitas Therapeutics General Information

Lead program IMT-009 (anti-CD161 mAb) in Phase 1/2a clinical trials. Preclinical data shows enhanced tumor-killing, increased cytokine production, and improved survival through CD161-CLEC2D pathway modulation.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

IMT-009
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Immunitas Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Immunitas Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Immunitas Therapeutics's complete valuation and funding history, request access »

Immunitas Therapeutics Investors

Longwood Fund
Investor Type: Venture Capital
Holding: Minority
Agent Capital
Investor Type: Venture Capital
Holding: Minority
Medical Excellence Capital
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 11 investors. Get the full list »